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Dissecting the different steps of the processing and presentation of tumor-associated
antigens is a key aspect of immunotherapies enabling to tackle the immune response
evasion attempts of cancer cells. The immunodominant glycoprotein gp100209-217 epi-
tope, which is liberated from the melanoma differentiation antigen gp100PMEL17, is part
of immunotherapy trials. By analyzing different human melanoma cell lines, we here
demonstrate that a pool of N-terminal extended peptides sharing the common min-
imal epitope is generated by melanoma proteasome subtypes. In vitro and in cel-
lulo experiments indicate that ER-resident aminopeptidase 1 (ERAP1)—but not ERAP2—
defines the processing of this peptide pool thereby modulating the T-cell recognition of
melanoma cells. By combining the outcomes of our studies and others, we can sketch the
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complex processing and endogenous presentation pathway of the gp100209-217-containing
epitope/peptides, which are produced by proteasomes and are translocated to the vesic-
ular compartment through different pathways, where the precursor peptides that reach
the endoplasmic reticulum are further processed by ERAP1. The latter step enhances
the activation of epitope-specific T lymphocytes, which might be a target to improve the
efficiency of anti-melanoma immunotherapy.
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 Additional supporting information may be found online in the Supporting Information sectionat the end of the article.
Introduction
Recognition and destruction of malignant cells by CD8+ cytotoxic
T lymphocytes (CTLs) are the underlying mechanisms of the three
leading approaches in cancer immunotherapy. At first, injection
of antibodies blocking the immune checkpoints CTLA-4 or PD-
1, which causes activation of patient’s T cells, has emerged as a
breakthrough in antitumor therapy. Secondly and thirdly, adop-
tive transfer of tumor-specific CTLs and therapeutic vaccination
are under preclinical as well as clinical investigation. A key fac-
tor in these latter immunotherapies is the selection of optimal
epitopes that are presented by major histocompatibility complex
(MHC) class I molecules to CTLs [1–3].
Tumor-expressed T cell epitopes are generated, transported,
and presented at the cell surface by MHC class I molecules via the
antigen processing and presentation pathway (APP). The majority
of these epitopes are produced by proteasome complexes, which
are the central proteolytic unities of the ubiquitin-proteasome-
system. Proteasomes generate MHC class I-restricted epitopes by
canonical peptide-bond hydrolysis as well as by post-translational
peptide splicing [4]. The proteasome’s 20S catalytic core particle
is arranged as four staggered rings, each containing seven non-
identical subunits. The outer rings contain the α subunits (α1–
α7), which form the ‘gates’ through which substrates enter and
products are released. Each of the two inner rings contains the β
subunits (β1–β7), three of which (β1, β2, and β5) harbor the six
active sites. In some hematopoietic cell types and in the presence
of type I and/or type II interferons, the β1, β2, and β5 standard
subunits are replaced by their alternative variants, the immuno-
subunits β1i/LMP2 (low molecular weight protein), β2i/MECL-
1 (multicatalytic endopeptidase complex like 1), and β5i/LMP7,
thereby forming de-novo synthesized immunoproteasomes [5, 6].
Besides standard- and immunoproteasome complexes, expres-
sion of intermediate- or mixed-type proteasomes containing both
standard- and immunoproteasome subunits have been detected
in various tumor cells as well as in healthy tissue [7–9]. These
proteasome isoforms quantitatively differ in their capability to
produce peptides although the existence of proteasome-specific
substrate cleavage sites and peptide products is still a matter of
discussion [7, 8, 10–15].
Following generation by proteasomes, the epitopes and their
precursor-peptides can be destroyed or further processed in the
cytosol by aminopeptidases such as tripeptidyl peptidase 2 (TPP2)
[16]. Peptides that survive this APP step are often translocated into
the ER lumen via TAP, where peptides can be further trimmed by
the IFN-γ inducible ER-resident aminopeptidases ERAP1 and/or
ERAP2 [17, 18]. In addition, ERAP1/2 has been shown to be con-
stitutively expressed in different tissues and tumor cells, where
the ERAP1 level correlated with MHC class I expression [19–21].
Whereas the generation of various, mainly viral, epitopes is
enhanced by ERAP1 [22], some tumor epitopes are destroyed
by ERAP1 activity [23, 24], thereby suggesting that N-terminal
trimming in the ER can be a key step of MHC class I antigen pre-
sentation and recognition of both infected and cancer cells [25].
So far, no precise role of ERAP2 in MHC class I epitope generation
could be defined, although its specificity has been characterized
to be distinct from ERAP1 activity [18, 26]. In general, the specific
mechanism of ERAP1 and/or ERAP2 function could not be clari-
fied so far. Although ERAP1 and ERAP2 have been shown to trim
peptides in solution separately and also completing each other’s
activity, ERAP1/2 heterodimer formation has been proposed to
exist in cells. However, the exact nature of the in vivo heterodimer
could not be demonstrated so far. An artificially created ERAP1-
ERAP2 heterodimer was shown to change the enzymatic param-
eters of ERAP1 leading to increased peptide trimming efficacy of
the ERAP1/2 complex in vitro [27]. Furthermore, ERAP1-ERAP2
heterodimer constructs have been shown to trim precursor pep-
tides while they are bound to MHC class I molecules, albeit no
direct ERAP/MHC interaction could be detected [28]. Peptides
are further handled by the peptide loading complex, which inserts
the peptide into the binding groove of the MHC class I molecules
according to their sequence affinity [29, 30].
Initially identified by the Rosenberg lab, the melanoma-
associated glycoprotein 100 (gp100)209-217 epitope has been fre-
quently targeted in clinical anti-melanoma trials, mainly in its
anchor-modified form (gp100209-217/(T210M)) to enhance HLA-
A*02:01 binding affinity [31–34]. The T210M substitution not
only improves the binding of the gp100209-217/T210M epitope to
HLA-A*02:01 but also alters significantly the proteasomal pro-
cessing of that antigenic sequence [35]. The gp100209-217 epitope
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is derived from the melanocyte differentiation protein gp100 (also
called PMEL or Pmel17), which belongs to the group of differen-
tiation antigens expressed by tumor cells and healthy tissue of
origin. PMEL can be frequently detected in metastatic melanomas
making it a suitable target for cancer immunotherapy [36].
The gp100209-217/T210M epitope can be recognized by CTLs
not only in its minimal version but also in its N-terminal
extended versions gp100207-217/T210M and gp100208-217/T210M. The
latter peptides bind the HLA-A*02:01 complex with lower affin-
ity than the gp100209-217/T210M epitope. Any N-extended version
of gp100209-217 (from gp100205-217 to gp100208-217) produced by
proteasomes can be trimmed in vitro by ERAP1 to the length of
the minimal gp100209-217 epitope, whereas further degradation
seems to be prevented [35]. According to these results, ERAP-
mediated trimming of this pool of peptides in melanoma cells
should determine the CTL response and therefore affect the effi-
cacy of immunotherapies targeting this epitope.
To test this hypothesis, we investigated in vitro and in
cellulo how ERAP1 and ERAP2 control the activation of the
gp100209-217/(T210M)-specific CTL clone, which recognizes both WT
gp100209-217 and mutant gp100209-217/(T210M) epitopes. The exper-
imental outcomes provided the missing information to construct
the APP model of this critical melanoma antigen.
Results
Cleavage preferences of proteasome subtypes
expressed in human melanoma cell lines
Since the generation and presentation of the pool of gp100209-217-
containing peptides is influenced by the proteasome isoform con-
tent of the cell [10, 12, 13, 35], we investigated the protea-
some catalytic-subunit composition in two human melanoma cell
lines, i.e. the gp100-expressing Ma-Mel-63a cells and the gp100-
negative Ma-Mel-86a cells (Supporting Information Fig. 1A). Both
melanoma cell lines expressed a mixed population of protea-
some isoforms including what we inferred being the intermediate-
type proteasome carrying the β1/delta, β5i/LMP7, and β2/Z or
the β1i/LMP2, β5i/LMP7, and β2/Z subunits (Fig. 1A). Accord-
ingly, analysis of purified proteasomes by two-dimensional gel
electrophoresis revealed the assembly of intermediate-type pro-
teasomes containing the two immunosubunits ß1i/LMP2 and
ß5i/LMP7 in the absence of ß2i/MECL-1 (Supporting Informa-
tion Fig. 1B). However, compared to isolated human spleen, ß1i
and ß5i expression was considerably less pronounced in both
melanoma cell lines. Based on these observations, we conclude
that the melanoma cell lines Ma-Mel-63a and Ma-Mel-86a express
intermediate-type proteasomes containing ß1i/LMP2, ß5i/LMP7
and ß2/Z.
Exposure of melanoma cell lines to INF-γ, which could be a
frequent situation in the tumor and microenvironment, resulted
in the up-regulation of all three immunosubunits including
the β2i/MECL-1 subunit (Fig. 1B), thereby suggesting that the
Figure 1. Proteasome content in human melanoma cell lines. (A) Sub-
unit composition of proteasome complexes purified from the cell lines
Ma-Mel-63a and Ma-Mel-86a analyzed by immunoblotting using anti-
bodies against the indicated proteasome subunits (two technical repli-
cates, single representative experiment). T2 cells (deficient for β1i/LMP2
and β5i/LMP7) and T2.27 cells—expressing murine β1i/LMP2, β5i/LMP7,
as well as human β2/Z—were used as control and α4 served as loading
control. (B) Induction of immunoproteasome subunits in Ma-Mel-63a
and Ma-Mel-86a cells upon IFN-γ treatment analyzed by immunoblot-
ting using antibodies, as indicated. Melanoma cells were exposed to
200 U/mL IFN-γ for 48 h and compared to HeLa cells (two biological
replicates, one out of two independent experiments is shown). GAPDH
served as loading control.
modification of the proteasome isoform content is modifiable in
these cell lines.
To investigate the specific proteolytic activity of melanoma-
derived 20S proteasomes we performed in vitro processing experi-
ments of the synthetic peptide gp100201-230 using 20S proteasomes
purified from the two melanoma cell lines. The substrate and pep-
tide products were measured by mass spectrometry (MS) and the
MS outcomes were analyzed by the quantification with minimal
effort (QME) method, which allowed to quantify the amount of
each peptide product and to compute the substrate cleavage-site
usage, i.e. the substrate site-specific cleavage strength (SCS) [37].
Correlation between in vitro experiments carried out with purified
20S proteasomes and in cellulo and in vivo experiments has been
demonstrated in various studies [7, 8, 12, 13, 38–47]. Proteasomes
were purified from cell lines grown in the absence of inflammatory
stimuli to analyze their baseline activity. Consistently with previ-
ous studies [10, 12, 13, 35], the minimal gp100209-217 epitope
was not detectable in melanoma proteasome digestions, whereas
its N-terminal extended versions could be quantified (Fig. 2A).
In terms of substrate degradation and preferences of cleavage
within the synthetic gp100201-230 peptide, the proteasomes puri-
fied from the two melanoma cell lines showed a similar degrada-
tion rate and a similar cleavage pattern, which differed from that
C© 2019 The Authors. European Journal of Immunology published by
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Figure 2. Gp100-related activity of 20S proteasomes isolated from different human cell lines and tissues. (A) Absolute amount of the synthetic
substrate gp100201-230 and of the gp100209-217-containing peptides in the in vitro kinetic assays with 20S proteasome purified from Ma-Mel-63a and
Ma-Mel-86a cell lines. The absolute amount of the peptide products was computed by quantification with minimal effort (QME). Values represent
the mean and lines the SD of two independent experiments and two to three technical replicates. (B) Relative frequency of cleavage (SCS) after
each substrate residue of the synthetic substrate gp100201-230 by 20S proteasomes purified from Ma-Mel-63a and Ma-Mel-86a cell lines as well as
from human erythrocytes and spleen. SCS was computed by QME from the in vitro kinetic assays measured by MS. Values represent the mean and
lines the SD of two independent experiments and two or three technical replicates for the melanoma proteasome and two technical replicates for
the human erythrocytes and spleen. (C) Scheme of the applied substrates and detected peptides throughout the study.
of proteasomes purified from human erythrocytes (standard pro-
teasome) and spleen (immunoproteasome-enriched) (Fig. 2A and
B). 20Smelanoma proteasomes produced the gp100205-217 peptide
in considerably larger amounts than the shorter N-extended ver-
sions of the gp100209-217 epitope (Fig. 2A and C). This was medi-
ated by a strong cut between S204 and S205 at the gp100205-217
N-terminus (Fig. 2B). All substrate cleavage sites used by ery-
throcyte and spleen proteasomes were used also by melanoma
proteasomes, thereby confirming the hypothesis that proteasome
isoforms largely cleave after the same residues although with sig-
nificant quantitative differences [10, 37]. The SCSs of erythro-
cyte and spleen proteasomes were similar to those of a previous
study carried out with 20S proteasome purified from these speci-
mens [10], thereby confirming the robustness of this type of assay
and analysis.
ERAP1 provokes degradation of the gp100205-217
substrate as well as gp100209-217 epitope generation
As already anticipated, 20S proteasomes obtained frommelanoma
cell lines did not produce the minimal gp100209-217 epitope in
detectable amounts, confirming the result of previous studies car-
ried out with various proteasomes and conditions [10, 12, 13, 35].
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Table 1. Kcat/KM of the trimming of N-extended versions of the
minimal gp100209-217 epitope by recombinant ERAP1. The
Michaelis–Menten constants were computed from the in vitro
digestions of the 50 µM synthetic peptides gp100205-217, gp100206-217,
gp100207-217, gp100208-217, gp100209-217 by 2.5 ng recombinant ERAP1
over time. The MS-measured results of the digestions were published
previously [35]. Means and standard deviations of two independent
experiments are shown. Kinetic parameters were estimated in a
Bayesian framework resulting in parameter distributions and
therefore providing confidence estimates (see also Supporting
Information Fig. 2)
Substrate kcat/KM [mM−1 min−1]
gp100209-217 1.50 ± 1.51
gp100208-217 17.68 ± 1.99
gp100207-217 14.12 ± 2.11
gp100206-217 37.72 ± 5.15
gp100205-217 17.37 ± 2.91
Two N-extended versions – i.e. gp100208-217 and gp100207-217 -
have been shown to induce CTL activation in vitro [35]. They
are produced in significant smaller amounts than the gp100205-217
peptide by 20S proteasome purified from melanoma cell lines
(Fig. 2A) and other cell types [35], though. These quantitative
observations suggest that the trimming of the N-extended versions
of the minimal gp100209-217 epitope could play a significant role
in the presentation of the gp100209-217 epitope by melanoma cells
to CTLs. Therefore, we computed the in vitro efficiency in trim-
ming N-extended versions of the minimal gp100209-217 epitope by
recombinant ERAP1. To this end we made use of a mathemati-
cal model of ERAP1 activity and inferred the kinetic parameters
based on the quantitative substrate degradation measurements
of the digestions of the gp100205-217, gp100206-217, gp100207-217,
gp100208-217, and gp100209-217 synthetic peptides previously pub-
lished [35] (Supporting Information Fig. 2A). The degradation
kinetics of the substrates recapitulated a Michaelis–Menten-like
reaction. Thus, we set out to estimate the Michaelis–Menten
parameters kcat, KM, and kcat/KM (Supporting Information Fig.
2B), and reported the kcat/KM values (Table 1), which gave
the best confidence in our model. The estimated kcat/KM value
of gp100209-217 peptide was significantly lower compared to the
parameters of the N-extended versions, thereby reflecting the
fact that the epitope was not trimmed by ERAP1 in those condi-
tions. The ERAP1-mediated trimming efficiency for the substrates
gp100208-217, gp100207-217, and gp100205-217 was comparable. On
the contrary, the substrate gp100206-217 was processed with high-
est efficiency, most likely due to a higher kcat (Table 1 and Sup-
porting Information Fig. 2B).
Since the gp100205-217 peptide is generated in high amounts
by the proteasome of the melanoma cell lines (Fig. 2A), we fur-
ther investigated the ERAP1/2 dynamics of gp100205-217 process-
ing. When this peptide is trimmed by ERAP1, the gp100206-217,
gp100207-217, gp100208-217, and gp100209-217 peptides/epitope are
generated and no shorter peptide fragments could be detected
(Fig. 3A and B). When we used very high ERAP1 enzyme con-
centrations (2 µg/mL) a barely detectable gp100210-217 pep-
tide product was measured (Supporting Information Fig. 3A).
Normal concentration of ERAP2 could generate only a small
Figure 3. ERAP1 and ERAP2 trimming activity of the synthetic substrate gp100205-217. (A–F) The epitope precursor peptide gp100205-217 was digested
in vitro for 4 h by ERAP1 and/or ERAP2 and the generated peptide fragments were measured by LC–MS. The HPLC-profiles are zoomed from 35 to
50 min. Addition of enzymes as follows: (A) substrate gp100205-217 control, (B) ERAP1 (3 ng), (C) ERAP2 (3 ng), (D) ERAP1/2 ratio I:II (1 ng ERAP1/2 ng
ERAP2), (E) ERAP1/2 ratio I:I (1.5 ng ERAP1/1.5 ng ERAP2), and (F) ERAP1/2 ratio II:I (2 ng ERAP1/1 ng ERAP2). The relative MS ion signal of the peptides
gp100209-217 (9mer epitope), gp100208-217 (10mer), gp100207-217 (11mer), and gp100206-217 (12mer), which were identified by LC–MS/MS, is indicated.
One out of two independent experiments is displayed.
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Figure 4. Endogenous gp100209-217 epitope generation is inhibited by leucinethiol. (A) LC–MS profiles of in vitro substrate degradation of the 13mer
gp100205-217 precursor peptide by ERAP1 without and with inhibitor leucinethiol after 180 min incubation and (B) corresponding relative substrate
degradation. SD (of mean) of duplicate determinations is shown as representative data from two independent experiments. (C) Ma-Mel-63a and
(D) UKRV-Mel-15a cells were exposed to 30 µM leucinethiol for 16 h or to DTT as solvent control and were co-incubated with gp100209-217-specific
T lymphocytes for 16 h. IFN-γ release by gp100-specific CTLs was measured by IFN-γ ELISA. T2 cells without and with gp100209-217 peptide were
used as control for T cell specificity. Data are displayed as mean + SD of three technical replicates. One independent experiment out of two is
shown (Student’s t-test; *p < 0.05; **p < 0.01). (E) Specific activity of ERAPs in cell lysates of leucinethiol treated Ma-Mel-63a and UKRV-Mel-15a cells.
Specific activity was measured through incubation of the cell lysates with the H-Leu-AMC- or the H-Arg-AMC-substrate, which display ERAP1 and
ERAP2 activity, respectively. DTT-treated cells served as control. Data are displayed as mean and SD of two technical replicates (one out of two
independent experiments).
amount of the gp100207-217 epitope (Fig. 3A and C), which could
be enhanced by using high ERAP2 enzyme concentrations (Sup-
porting Information Fig. 3B and C). No smaller peptide prod-
ucts could be clearly identified when we used the synthetic pep-
tides gp100207-217, gp100208-217, and gp100209-217 as substrates
(Supporting Information Fig. 3B and C and data not shown).
This limited trimming activity of ERAP2 is substrate specific since
the cleavage of the HIV-gp160313-327 precursor peptide was effi-
ciently carried out as expected (Supporting Information Fig. 4A
and B) [17]. In ERAP1/2 digestions, the gp100205-217 substrate
degradation rate directly correlated with the ERAP1:ERAP2 rela-
tive ratio. Accordingly, more products were detectable by increas-
ing the ERAP1:ERAP2 ratio, although in those assays where
ERAP2 was present, the gp100206-217 peptide product could not be
identified (Fig. 3A–F).
To further test our hypothesis that ERAP1 promotes the gen-
eration of immunogenic gp100209-217-containing epitopes, we
performed in vitro and in cellulo experiments by using the met-
alloprotease inhibitor leucinethiol, which targets ERAP1. Consis-
tently, addition of leucinethiol to the in vitro digestion resulted
in a blockade of gp100205-217 degradation and stabilization of
the precursor peptide (Fig. 4A and B). Furthermore, activation
of a gp100209-217-specific CTL clone was significantly reduced by
ERAP1 inhibition in Ma-Mel-63a (Fig. 4C) and UKRV-Mel-15a
melanoma cells (Fig. 4D), which both express the gp100 antigen
and HLA-A*02:01. As activity control, the ability of leucinethiol
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Figure 5. Quantification of ERAP1 and ERAP2 in different melanoma cell lines compared to HeLa cells. (A and B) absolute quantification of ERAP1
(50 µg protein loaded) and ERAP2 (100 µg protein loaded) concentration analyzed by western blot in HeLa, UKRV-Mel-15a, Ma-Mel-63a, and Ma-Mel-
86a cells using different concentrations of recombinant ERAP1 or ERAP2 as standard. In (B) the protein band densities from independent western
blot assays for ERAP1 (n = 4) and ERAP2 (n = 3) has been measured and mean + SD are shown. (C) Ratios of the ERAP1 content were analyzed by
MS label-free quantification (LFQ) (UKRV-Mel-15a/HeLa cells; Ma-Mel-63a/HeLa cells; Ma-Mel-86a/HeLa cells) (mean + SD, two biological replicates
measured three times). (D) ERAP1 protein expression analyzed by immunoblotting in Ma-Mel-63a and Ma-Mel-86a cells upon IFN-γ treatment
(200 U/mL IFN-γ for 48 h). HeLa cells were used as control and β-actin as loading control. One out of two independent experiments is shown. (E)
Allelic variants of ERAP1 were analyzed by sequencing of cloned full length ERAP1 constructs derived from total RNA of HeLaA2+ cells, Ma-Mel-63a,
Ma-Mel-86a, and UKRV-Mel-15a cells. Previously described allelic variants found in five out of five independent clones (2/2 for HeLaA2+ cells) are
depicted.
treated cell lysates to trim the H-Leu-AMC or the H-Arg-AMC
substrate was analyzed. As expected, the turnover of the H-Leu-
AMC—representing ERAP1 activity—was significantly reduced in
the presence of leucinethiol, whereas the H-Arg-AMC substrate—
representing ERAP2 activity—was not affected (Fig. 4E).
ERAP1, but not ERAP2, promotes activation of
gp100209-217-specific CTL clones by melanoma cell lines
These results suggested a beneficial impact of ERAP1 rather
than ERAP2 in defining the presentation of the gp100209-217-
containing peptides/epitope by melanoma cells to CTLs. We tested
this hypothesis and the ERAP1/2 content in human melanoma
cell lines Ma-Mel-63a, Ma-Mel-86a, and UKRV-Mel-15a. They all
expressed both ERAP1 and ERAP2, although ERAP2 expression
was lower than ERAP1 with different ERAP1:ERAP2 ratio among
the melanoma cell lines (Fig. 5A–C). Upon exposure to IFN-γ,
ERAP1 expression was enhanced in both Ma-Mel-86a cells and
Ma-Mel-63a cells (Fig. 5D) and also in UKRV-Mel-15a cells as
shown before [24]. Since ERAP activity could be influenced by
the various polymorphisms that these enzymes have, we analyzed
the ERAP1 alleles present in the investigated cell lines. Amongst
others, we observed two described polymorphisms associated with
the risk of cancer development [48, 49]. The R127P polymorphism
in HeLa, UKRV-Mel-15a and Ma-Mel-63a and the Q730E mutation
in Ma-Mel-86a cells suggest an altered peptide trimming activity
in the latter [50] (Fig. 5E).
To test whether ERAP1 and ERAP2 could impinge upon the
presentation of the gp100209-217-containing peptides/epitope by
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Figure 6. ERAP1 but not ERAP2 impinges upon the activation of the gp100209-217-specific CTL clones. (A) IFN-γ-production of gp100209-217-specific
CTL clones incubated for 16 h with Ma-Mel-63a melanoma cells expressing HLA-A*02:01 and the gp100 antigen. Ma-Mel-63a cells were pretreated
with 30 nM ERAP1, ERAP2, and control siRNA for 72 h. T2 cells served as negative and gp100209-217-peptide loaded T2 cells as positive control, the
mean and the SD of three technical replicates are shown. Student’s t-test; p < 0.01. (B) Ma-Mel-63a cell RNA was analyzed for down-regulation
of ERAP1 and ERAP2. GAPDH served as loading control. (C) qPCR analysis of ERAP1 and ERAP2 down-regulation in Ma-Mel-63a cells. Relative
expression was calculated in comparison to control siRNA treated cells and 18S rRNA served as housekeeping gene. The means and SD of three
technical replicates are shown. (D) IFN-γ production of gp100209-217 specific cytotoxic T cells incubated for 16 h with gp100 transfected HeLaA2+ cells
(HeLa cells expressing HLA-A*02:01). HeLaA2+ cells were pretreated with siRNA against ERAP1 or ERAP2 as well as control siRNA for 72 h. T2 cells
served as negative and gp100209-217-peptide loaded T2 cells as positive control, the mean and the SD of three technical replicates are represented.
Student’s t-test; p < 0.01. (E) HeLa cell RNA was tested for down-regulation of ERAP1 and ERAP2 and overexpression of gp100. GAPDH served as
loading control. (F) qPCR analysis of ERAP1 and ERAP2 down-regulation in HeLaA2+ cells. Relative expression was calculated in comparison to
control siRNA treated cells and 18S rRNA served as housekeeping gene. The mean and SD of three technical replicates are shown. One out of two
independent experiments is shown (A–F).
melanoma cell lines to CTLs, we performed siRNA knock down
of either ERAP1 or ERAP2 in Ma-Mel-63a cells. In agreement
with our in vitro results, knocking down ERAP1 significantly
reduced the gp100209-217-specific CTL activation, whereas silenc-
ing ERAP2 displayed no significant alterations of the amount of
IFN-γ released by the CTL clone (Fig. 6A–C). Similar results were
obtained when we used UKRV-Mel-15a (Supporting Information
Fig. 5A and B) and gp100-transfectedHeLaA2+ (HeLa cells express-
ing HLA-A*02:01) cell line clones (Fig. 6D–F). This hints toward
the hypothesis that ERAP1, rather than ERAP2, promotes the acti-
vation of gp100209-217-specific CTLs by increasing the presentation
of gp100209-217 epitopes by melanoma cell lines as well as by other
cancer cell lines.
Discussion
The modified gp100209-217/(T210M) melanoma epitope has been
part of successful phase 2/3 clinical trials combining the
gp100209-217/(T210M) peptide with interleukin-2 application [34].
However, combined administration of gp100 peptides together
with the CTLA-4-antagonist ipilimumab in patients withmetastatic
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melanoma displayed no improvement in disease progression com-
pared to patients treated with ipilimumab alone, thereby suggest-
ing an insufficient presentation of the gp100209-217 epitope at least
in parts of the melanoma [51, 52].
Our results provide further information about the APP of the
gp100209-217-containing epitopes and specifically the role that
ERAP1 rather than ERAP2 plays in promoting epitope presen-
tation. Both in vitro kinetic analyses and in cellulo inhibitor and
siRNA experiments demonstrated that ERAP1 generates and sta-
bilizes the minimal gp100209-217 epitope. This is in contrast to the
MART-126-35 (melanoma antigen recognized by T cells) epitope
being destroyed by ERAP1 [24]. ERAP1 has been shown to be
constitutively expressed in tumor cells, even in the absence of
IFN-γ [19, 24]. Analyzing three different melanoma cell lines, we
found differences in ERAP1 expression (Fig. 5). We could detect
two ERAP1 polymorphisms (R127P and Q730E), which are corre-
lated with an increased risk of cancer development [49, 53]. How-
ever, only the Q730E mutation has been shown to display reduced
peptide trimming activity suggesting an impaired gp100209-217 epi-
tope generation in melanoma cells expressing the Q730E vari-
ant [50]. To note, we did not observe any effect of ERAP2 on
gp100209-217 epitope processing, neither in in vitro digestions—
using ERAP2 alone or in combination with ERAP1—nor in cellular
antigen presentation assays analyzing ERAP1/2 activity based on
ERAP natural expression in melanoma cells.
By combining the outcome of this and other studies [12, 13,
35, 54], we can sketch how gp100209-217-containing epitopes
are presented to CTLs: in the cytosol, proteasomes produce two
potential epitopes, i.e. gp100207-217/T210M and gp100208-217/T210M
that share the gp100209-217/T210M minimal sequence
IT/MDQVPFSV. The WT gp100207-217 and gp100208-217 pep-
tides bind with low affinity to the HLA-A*02:01 complex,
therefore their in vivo immunogenicity is disputable, and these
are most likely only sources for the gp100209-217 generation in
the ER. In contrast, the T210M gp100207-217 and gp100208-217
peptides bind to the HLA-A*02:01 complex with higher affinity
and trigger a stronger CTL response in vitro than the WT
gp100209-217 epitope [35]. Furthermore, melanoma proteasomes,
which contain intermediate-type proteasomes, as shown for
both Ma-Mel-63a and Ma-Mel-86a cells here as well as in
previously published literature [7, 13], abundantly generate
the N-extended version of the gp100209-217-epitope, i.e. the
gp100205-217 precursor. In the cytosol, the epitopes (and likely
also their N-extended precursors) can be destroyed by TPP2 [54].
The peptides that survive this step can be translocated into
the ER lumen via TAPs and to the endosomal compartment by
another unknown carrier. In the ER, the peptides gp100205-217,
gp100206-217, gp100207-217, and gp100208-217 can be trimmed by
ERAP1—but not by ERAP2—thereby augmenting the amount of
the gp100209-217-containing epitopes, as shown in the present
study and in ref. [35]. For those gp100209-217/T210M-containing
epitopes that followed the canonical TAP-dependent pathway,
the allocation into the HLA-A*02:01 binding groove is likely
mediated by the peptide loading complex. For the portion of
Figure 7. APP of the gp100209-217/T210M-containing epitopes/peptides. Explanation of the pathway can be found in the discussion section. With the
nomenclature gp100207-217/T210M and gp100208-217/T210M as well as gp100209-217/T210M, we refer to both WT and T210M peptides. In detail, differences
between the WT and the T210M peptides are disclosed in the Discussion section. Reproduced with permission from ref. [ 5].
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the gp100209-217 epitope that is translocated into the endosomal
pathway via an alternative route, the function of tapasin is not
mandatory to efficiently present the gp100209-217 epitope at the
cell surface [54] (Fig. 7).
The APP that triggers a response of gp100209-217/T210M-specific
CTLs is therefore branched and can be carried out with success
independently of several proteins/enzymes. This supports the use
of this pool of epitopes/peptides in immunotherapy because a
diversified APP can be a potent tool to tackle the immune-response
escape attempts implemented by cancer. For example, we can
speculate that even in case that cancer compromises either TAP or
tapasin, the presentation of the gp100209-217/T210M-containing epi-
topes could be enhanced in melanoma by inhibiting TPP2 and/or
stimulating ERAP1.
Materials and methods
Cell culture
Melanoma cell lines have been described previously [55].
Melanoma cells, HeLa cells, the TAP-deficient T2 cell line, and
T2.27 cells expressing murine β1i/LMP2 and β5i/LMP7 [56] were
grown in RPMI1640 (Biochrom) containing 10% FCS, 2 mM L-
glutamine, and 100 U/mL penicillin/streptomycin (additives from
PAA Laboratories). HeLa transfectants, expressing HLA-A*02:01
(HeLaA2+) were grown in medium supplemented with 2 µg/mL
puromycin and T2.27 cells in the presence of 0.1 mg/mL G418
[56, 57].
Immunoblotting and 2-dimensional gel
electrophoresis
Western blot was performed as described [58]. Briefly, 25 µg pro-
tein of cell lysate or 100 µg for gp100 detection and 1 µg of purified
20S proteasome per lane were separated on SDS-PAGE, trans-
ferred to PVDF-membranes and were immunoblotted for protea-
some subunits (all laboratory stock), β1i/LMP2 (Abcam), gp100
(Abcam), and GAPDH (Santa Cruz). For ERAP1/2 detection and
quantification 50 or 100 µg protein of cell lysate were blotted
and probed with ERAP1 (6H9, R&D Systems), ERAP2 (3F5, R&D
Systems), and β-actin (Sigma-Aldrich). Membranes were devel-
oped with ECL (GE Healthcare). For absolute quantification of
ERAP1/2 in human cell lines, the western blot signal was com-
pared to recombinant ERAP1 (10, 50, 75, and 100 ng) or ERAP2
(5, 10, 20, and 50 ng), and was quantified using ImageJ software.
ERAP content in cell lysates was calculated from the resulting
standard curves.
To separate the subunits of the 20S proteasome complex,
isoelectric focusing by carrier ampholytes was combined with
SDS-PAGE. Proteasomes were applied to a carrier ampholyte
isoelectric focusing gel. In the second dimension, proteins were
loaded onto SDS-PAGE and stained with Coomassie brilliant blue
G-250. Proteasome subunits could be identified based on their
migration behavior in comparison to reference electrophoreses of
selected proteasomes [59].
20S proteasome and recombinant ERAP1/2
20S proteasomes were purified from frozen melanoma cell lines
and from human spleen and erythrocytes as described [60].
Recombinant human ERAP1 and ERAP2 were purchased from
R&D Systems.
Peptides
The AHSSSAFTITDQVPFSVSVSQLRALDGGNK gp100201-230
polypeptide as well as the gp100209-217 9mer ITDQVPFSV and
the 10mer TITDQVPFSV, 11mer FTITDQVPFSV, 12mer AFTIT-
DQVPFSV, 13mer SAFTITDQVPFSV derive from the human
melanocytic protein gp100PMEL17 sequence. The HIVgp160313-327
precursor peptide containing the gp160319-327 epitope derives
from the HIV gp160 glycoprotein. All peptides were synthesized
using Fmoc solid phase chemistry.
In vitro digestion of short fluorogenic peptides
To control inhibition of peptidase activity in Ma-Mel-63a and
UKRV-Mel-15a cells, cells exposed to leucinethiol (solved in
0.5 mM DTT) or DTT were lysed in 50 mM Tris-HCl (pH 7.5),
50 mM NaCl, 5 mM MgCl2, 0.1% TritonX, and homogenized with
a Dounce homogenizer. Specific peptidase activity was determined
by incubation of 3 µg cell lysate with 50 µMH-Leu-AMC or H-Arg-
AMC (Bachem) in 25 mM Tris-HCL (pH 7.5), 150 mM NaCl assay
buffer for 30 min at 37°C, and computed as [nmol AMC/min/µg
cell lysate].
Recombinant ERAP1 and ERAP2 enzymatic activity was tested
by degrading the substrates H-Leu-AMC and H-Arg-AMC for
ERAP1 and ERAP2, respectively. We used various substrate con-
centrations (10-200 µM) and 0.1 µg ERAPs in 25mMTris (pH 7.5).
The specific activity was 0.156 nmol/min/µg (ERAP1) and 0.05
nmol/min/µg (ERAP2) and comparable to the activities described
by the manufacturer (R&D systems).
The fluorescence was measured by Tecan fluorometer using
excitation 360 nm and emission 460 nm wavelength in a kinetics
experiment (0–20 min). The free AMC calibration curve was done
by measuring the fluorescence of free AMC at various concentra-
tions (0–1 µM).
In vitro digestion of synthetic peptide substrate
by purified 20S proteasome
The synthetic peptide gp100201-230 (40 µM) was digested by 3 µg
of purified 20S proteasomes in 100 µL TEAD buffer (20 mM Tris,
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1 mM EDTA, 1 mM NaN3, 1 mM DTT, pH 7.2) in kinetic experi-
ments (0–8 h) at 37°C. For the assays performed with melanoma
proteasomes we carried out two biological replicates, each of them
measured 2–3 times byMS. For the assays performedwith erythro-
cyte and spleen proteasomes we carried out one assay, measured
twice by MS since the outcome recapitulated the results described
previously [10]. Liquid chromatography–mass spectrometry (LC-
MS) analyses of polypeptide digestion products were performed
using the ESI-ion trap instrument DECA XP MAX (ThermoFisher
Scientific, USA) as previously described [61]. Database search-
ing was performed using SpliceMet’s ProteaJ, which allowed the
identification of spliced and non-spliced peptide products [61].
Quantification of proteasome-generated peptides and computa-
tion of the substrate SCS was carried out by applying the QME
(Quantification with Minimal Effort) method to the LC-MS analy-
ses [37]. QME estimated the absolute content of peptide products
based on their MS ion peak area measured in the digestion probe.
The QME algorithm parameters were empirically computed in our
previous study [37] and here applied. SCS describes the relative
frequencies of proteasome cleavage after any given residue of the
synthetic polypeptide substrates [37]. The SCS values shown in
this study are the average of SCS measured over time [37].
Analysis of in vitro digestions of precursor peptides
with ERAPs
Fifty micromolar of peptides were digested in vitro with 3 ng
recombinant ERAP1 or recombinant ERAP2 in 20 µL assay buffer
(25 mM Tris, pH 7.5, 150 mM NaCl, 0.5 µg/mL albumin) at 37°C.
For high enzyme concentrations, 25 µM of peptides were digested
with 2 µg/mL ERAP1 or ERAP2 [18]. To inhibit ERAP1 activ-
ity, 3 ng recombinant enzyme were pre-incubated with 30 µM
leucinethiol at room temperature for 20 min and then applied to
in vitro processing experiments. For the analysis of the digestion
products obtained from the gp100205-217 precursor peptide, differ-
ent ERAP1/ERAP2 ratios (pre-incubation 30 min at room temper-
ature) were used, total enzyme concentration (3 ng/20 µL diges-
tion volume) and peptide concentration (50 µM) were constant,
recombinant ERAP1/ERAP2 ratio is indicated in Fig. 3. The diges-
tion period was 4 h. Experiments were performed at least twice.
Peptide products were identified by LC-MS/MS, as described for in
vitro proteasome experiments (see above). Substrates’ abundance
was quantified through the titration of synthetic peptides.
To analyze the substrate trimming dynamics of ERAP1, we
applied amathematical model describingMichaelis–Menten kinet-
ics. We estimated the kinetic parameters of the model Km and
kcat of the trimming of the synthetic substrates gp100205-217,
gp100206-217, gp100207-217, gp100208-217, gp100209-217 by purified
ERAP1 in two of the kinetics experiments described elsewhere
[35].
The model reactions can be depicted as follows: S + E ↔ [SE]
→ P + E, resulting in the ordinary differential equation model
describing substrate degradation over time t: dS/dt = -E*kcat*S
/ (KM+S), where S is the substrate, P is the sum of all products,
E is the enzyme ERAP1; KM is the Michaelis–Menten constant;
kcat describes the trimming of the substrate to products P (also
maximal velocity). According to our model, although a large range
of KM and kcat values could result in a good model fit with the
experimental data, the KM and kcat were strongly correlated (Sup-
porting Information Fig. 2B). Hence, we could compute ERAP1
efficiency as the ratio kcat/KM and then derivate the parameter
confidence distribution for KM and kcat (Supporting Information
Fig. 2B). The parameters kcat, KM, and kcat/KM were estimated
using exact Bayesian inference in a Markov Chain Monte Carlo
scheme. The latter resulted in posterior parameter distributions
(rather than single point estimates) and therefore we could also
provide with an estimate of the parameter uncertainty. The medi-
ans and standard deviations (SD) of the marginal posterior param-
eter distributions are reported in Table 1.
Identification and quantification of ERAP1 in the lysates of
different cell lines were performed as described before [62]. LC-
MS runs were conducted as follows: samples were trapped and
then analyzed by nanoscale LC-MS/MS measurements using a Q
Exactive Plus mass spectrometer coupled with an Ultimate 3000
RSLCnano (ThermoFisher Scientific). Protein identification and
relative label-free quantification were performed using MaxQuant
software version 1.6.0.1 [62] and Andromeda label-free quantifi-
cation parameters were set to default. Spectra were matched to a
human database (20 244 reviewed entries, downloaded from swis-
sprot.org), a contaminant, and decoy database. In addition, pro-
tein identifications were calculated with FDR = 1% and proteins
with one razor peptide per protein were used for identification.
Lysates were digested twice and analyzed three times.
T-cell stimulation
For CTL-experiments PBLs obtained from healthy donors after
informed consent and Ethical Committee (Charite´) approval
were transduced with the gp100209–217/(T210M) epitope-specific
T-cell receptor (recognizing the IMDQVPFSV peptide and the
ITDQVPFSV peptide) [63]. In CTL assays the following target cells
were used: UKRV-Mel-15a andMa-Mel-63a cells exposed to 30 µM
leucinethiol (Bachem) (solved in 0.5 mM DTT) for 16 h, HeLaA2+,
Ma-Mel-63a, UKRV-Mel-15a, and T2 cells. In order to silence
ERAP1/2, HeLaA2+ cells, Ma-Mel-63a or UKRV-Mel-15a cells were
transfected with 30/100 nM siGENOME human ERAP1 siRNA-
SMARTpool (#M-005787-02-0005, Dharmacon) or 30/100 nM
siGENOME human ERAP2 siRNA-SMARTpool (#M-005934-02-
0005, Dharmacon) for 72 h. As control, 30/100 nM non-targeting
siRNA (#D-001206-13-05, Dharmacon) was employed. HeLaA2+
cells were transiently transfected with 3 µg of an expression plas-
mid encoding gp100PMEL17 (pcDNA3.1/myc-HIS/gp100mel [40])
for 24 h according to the manufacturer’s instructions (Lipofec-
tamine 2000, Invitrogen), followed by co-incubation of target
cells and gp100209–217/T210M specific T lymphocytes for 16 h, IFN-
γ-release in the supernatants was determined by human IFN-γ
ELISA Kit (Biolegend). Co-incubation with T2 cells served as neg-
ative control, whereas T2 cells loaded with 1 µg/mL gp100209-217
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peptide for 16 h were used as positive control. T cell assays pre-
sented in this work were performed compliant to MIATA guide-
lines.
Confirmation of siRNA knock down by RT-PCR
Total RNA from HeLaA2+ cells, Ma-Mel-63a and UKRV-Mel-15a
cells was isolated using the Trizol reagent (Thermo Fisher Scien-
tific). Reverse transcription was performed with M-MLV Reverse
Transcriptase (Promega). Expression of ERAP1/2 was analyzed
by RT-PCR and qPCR. GAPDH and gp100 were used as controls.
RT-PCR primers were used as indicated: ERAP1 forward 5´-CC
ACTCCTTCATGGTGTCAG-3´ and reverse 5´-GCAACAGTCAC
AGATTTCAC-3´; ERAP2 forward 5´-CTGCTTAACAGCCATCTTGC-
3´ and reverse 5´-CATCACCTAACTTGGCTTGG-3´; gp100 forward
5´-AGTTCCAGGGACCACAGATG-3´ and reverse 5´-CCAGGCAT
GATAAGCTGGGT-3´; GAPDH forward 5´-CCGTCAAGGCTGAGAA
CGGG-3´ and reverse 5´-GCCATGCCAGTGAGCTTCCC-3´. The
qPCR was performed using PowerUpTM SYBRTM Green Master
Mix (Thermo Fisher Scientific) with the following primers: ERAP1
forward 5´-CCCGACTTTCAGTCTGGTGCT-3´ and reverse 5´-TC
CCAAACCACTGGTGAGCCA-3´; ERAP2 forward 5´-GTGGCTTCA
CTTCATCAGGGGT-3´ and reverse 5´-TCCATGGCTCCAGGTGC
AAA-3´; 18S rRNA forward 5´-GTGGAGCGATTTGTCTGGTT-3´
and reverse 5´-AACGCCACTTGTCCCTCTAA-3´. Relative expres-
sion levels of the selected transcripts were normalized to the con-
trol siRNA and the housekeeping gene 18S rRNA and calculated
using the 2–Ct method.
Identification of ERAP1 allelic variants
To identify the expressed ERAP1 alleles the full length ERAP1
construct derived from total RNA of HeLaA2+ cells, Ma-Mel-63a,
Ma-Mel-86a and UKRV-Mel-15a cells was cloned into pCR 2.1
plasmid via TA cloning Kit (Thermo Fisher Scientific) and subse-
quently sequenced and analyzed for previously described allelic
variants according to Yao et al. [64].
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